Cambridge's Exonics Therapeutics Scores $40M Post author:Sam Post published:November 7, 2017 Post category:BioPharma Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group. Source: BioSpace You Might Also Like Bay Area's Galena Biopharma CEO Steps Down, Effective Immediately January 31, 2017 Norwegian Biotech Upstart Has Become a Potential Takeover Target February 19, 2017 Zoning Changes Kills Sale of Bristol-Myers Squibb's Connecticut Campus February 20, 2017